Improved PFS Outcomes With Elacestrant Correlate With CDK4/6 Duration in ER+/HER2– Metastatic Breast Cancer
Longer duration of CDK4/6 inhibitor prior to treatment with elacestrant correlated with progression-free survival (PFS) improvements in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer vs standard-of-care options.
DESTINY-Breast02 Confirms Benefit of Trastuzumab Deruxtecan in Previously Treated Patients With HER2+ Metastatic Breast Cancer
In the second-line setting, patients with advanced HER2-positive breast cancer derived a superior clinical benefit with trastuzumab deruxtecan compared with treatment with physician’s choice of treatment.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
